UY35103A - Compuestos de cefem 2-sustituidos - Google Patents

Compuestos de cefem 2-sustituidos

Info

Publication number
UY35103A
UY35103A UY0001035103A UY35103A UY35103A UY 35103 A UY35103 A UY 35103A UY 0001035103 A UY0001035103 A UY 0001035103A UY 35103 A UY35103 A UY 35103A UY 35103 A UY35103 A UY 35103A
Authority
UY
Uruguay
Prior art keywords
compounds
replaced
cefem
cefem compounds
lactamase
Prior art date
Application number
UY0001035103A
Other languages
English (en)
Inventor
Liao Xiangmin
Yamawaki Kenji
Aoki Toshiaki
Kusano Hiroki
Sato Jun
Pendrak Israil
Yokoo Katsuki
Neil David Pearson
Thalgi Reema
Original Assignee
Glaxo Group Ltd
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49955387&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY35103(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd, Shionogi & Co filed Critical Glaxo Group Ltd
Publication of UY35103A publication Critical patent/UY35103A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • C07D501/48—Methylene radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C07D519/06—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 containing at least one condensed beta-lactam ring system, provided for by groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00, e.g. a penem or a cepham system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • C07D501/48—Methylene radicals, substituted by hetero rings
    • C07D501/50—Methylene radicals, substituted by hetero rings with the 7-amino radical acylated by an aliphatic carboxylic acid, which is substituted by hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D505/00—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D505/10—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D505/12—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 substituted in position 7
    • C07D505/14—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 substituted in position 7 with hetero atoms directly attached in position 7
    • C07D505/16—Nitrogen atoms
    • C07D505/18—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof
    • C07D505/20—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof with the acylating radicals further substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D505/24—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof with the acylating radicals further substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen further substituted by doubly-bound nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Los compuestos de la presente invención se refieren a compuestos de cefem 2?sustituidos, que tienen un amplio espectro antimicrobiano, en particular exhiben una potente actividad antimicrobiana contra bacterias Gram negativas que producen beta?lactamasa y composiciones farmacéuticas que los comprenden
UY0001035103A 2012-10-29 2013-10-25 Compuestos de cefem 2-sustituidos UY35103A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261719523P 2012-10-29 2012-10-29

Publications (1)

Publication Number Publication Date
UY35103A true UY35103A (es) 2014-05-30

Family

ID=49955387

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035103A UY35103A (es) 2012-10-29 2013-10-25 Compuestos de cefem 2-sustituidos

Country Status (38)

Country Link
US (2) US20150299223A1 (es)
EP (1) EP2917223B1 (es)
JP (1) JP6316830B2 (es)
KR (1) KR20150081428A (es)
CN (2) CN107652310A (es)
AR (1) AR093261A1 (es)
AU (2) AU2013340469B2 (es)
BR (2) BR112015009460A2 (es)
CA (1) CA2889746A1 (es)
CL (1) CL2015001084A1 (es)
CR (1) CR20150224A (es)
CY (1) CY1121721T1 (es)
DK (1) DK2917223T3 (es)
EA (1) EA031881B1 (es)
ES (1) ES2717923T3 (es)
HK (1) HK1214826A1 (es)
HR (1) HRP20190603T1 (es)
HU (1) HUE042664T2 (es)
IL (1) IL238149A (es)
LT (1) LT2917223T (es)
MA (1) MA38039A1 (es)
ME (1) ME03359B (es)
MX (1) MX365534B (es)
MY (1) MY176987A (es)
NZ (1) NZ628527A (es)
PE (1) PE20151204A1 (es)
PH (2) PH12015500914A1 (es)
PL (1) PL2917223T3 (es)
PT (1) PT2917223T (es)
RS (1) RS58611B1 (es)
SG (2) SG11201502540RA (es)
SI (1) SI2917223T1 (es)
TR (1) TR201904001T4 (es)
TW (1) TWI625333B (es)
UA (1) UA117666C2 (es)
UY (1) UY35103A (es)
WO (1) WO2014068388A1 (es)
ZA (1) ZA201502174B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9527866B2 (en) * 2012-10-29 2016-12-27 Shionogi & Co., Ltd. Processes for production of intermediates for 2-alkyl cephem compounds
WO2014104148A1 (ja) * 2012-12-26 2014-07-03 塩野義製薬株式会社 セフェム化合物
JP6377570B2 (ja) * 2014-04-28 2018-08-22 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ ２−置換セフェム化合物を含有する医薬組成物
US10004750B2 (en) * 2014-09-04 2018-06-26 Shionogi & Co., Ltd. Salt of cephalosporin derivative, its crystalline solid and a method of manufacturing thereof
JP6814730B2 (ja) 2014-09-05 2021-01-20 ジェネンテック， インコーポレイテッド 治療用化合物およびその使用
JP6767969B2 (ja) 2014-09-05 2020-10-14 ジェネンテック， インコーポレイテッド がんの処置における使用のためのｐｃａｆおよびｇｃｎ５阻害剤としての式（ｉ）のフタラジン誘導体
CN104529735A (zh) * 2014-12-08 2015-04-22 苏州施亚生物科技有限公司 一种1-(5-溴-4-氯-2-氟苯基)-乙酮的合成方法
CN107406429B (zh) 2015-01-09 2021-07-06 基因泰克公司 哒嗪酮衍生物及其在治疗癌症中的用途
WO2016198691A1 (en) 2015-06-11 2016-12-15 Basilea Pharmaceutica Ag Efflux-pump inhibitors and therapeutic uses thereof
AU2016274576A1 (en) * 2015-06-11 2017-12-21 University Of Pittsburgh - Of The Commonwealth System Of Higher Education p62-ZZ chemical inhibitor
US9765026B2 (en) * 2015-08-28 2017-09-19 Scinopharm Taiwan, Ltd. Forms of apremilast and the process of making the same
US9751894B2 (en) * 2015-12-10 2017-09-05 Naeja-Rgm Pharmaceuticals Inc. Cephem compounds, their production and use
EP3579870A4 (en) 2017-02-07 2020-12-30 Seattle Children's Hospital (DBA Seattle Children's Research Institute) PHOSPHOLIPID ETHER (PLE) T CAR-LYMPHOCYTE TUMOR (CTCT) TARGETING AGENTS
JP7178355B2 (ja) 2017-02-28 2022-11-25 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞療法のための組成物および方法
CN106966914B (zh) * 2017-05-04 2019-02-22 无锡捷化医药科技有限公司 一种5-溴-4-氯-2-氨基苯乙酮的制备方法
US11311576B2 (en) 2018-01-22 2022-04-26 Seattle Children's Hospital Methods of use for CAR T cells
CN108892639B (zh) * 2018-08-13 2021-05-14 云南民族大学 一种高效环保制备喹诺酮类化合物的方法
CN113024581A (zh) * 2020-03-04 2021-06-25 刀鹏 一种盐酸头孢吡肟的合成方法
US20240132518A1 (en) * 2021-01-12 2024-04-25 Shanghai Senhui Medicine Co., Ltd. Cephalosporin antibacterial compound and preparation method therefor
CN113698365A (zh) * 2021-08-30 2021-11-26 成都大学 一种头孢地尔侧链的制备方法
CN116514679A (zh) * 2023-04-03 2023-08-01 南京工业大学 一种以廉价高效的硝酸季铵盐作为氧化剂的钯催化sp2和sp3碳氢键烯基化方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3487079A (en) * 1966-01-14 1969-12-30 Bristol Myers Co Certain alpha-amino bicyclic beta-lactam carboxylic acids
US3926983A (en) * 1974-08-30 1975-12-16 Squibb & Sons Inc 3-Heterothio{8 (alkoxycarbonyl)thioacetyl{9 cephalosporanic derivatives
US4268509A (en) 1978-07-10 1981-05-19 Fujisawa Pharmaceutical Co., Ltd. New cephem compounds and processes for preparation thereof
JPS5511600A (en) * 1978-07-10 1980-01-26 Fujisawa Pharmaceut Co Ltd Cephem compound, its salt, their preparation and remedy and prophylactic for microbism containing mainly the same
JPS56118085A (en) * 1980-02-25 1981-09-16 Takeda Chem Ind Ltd 2-methylcephalosporin derivative and its preparation
GB8816519D0 (en) 1987-07-23 1988-08-17 Ici Plc Antibiotic compounds
JPH0228185A (ja) 1988-04-14 1990-01-30 Tanabe Seiyaku Co Ltd セファロスポリン化合物及びその合成中間体
PH25965A (en) 1988-06-06 1992-01-13 Fujisawa Pharmaceutical Co New cephem compounds which have antimicrobial activities
GB8813945D0 (en) 1988-06-13 1988-07-20 Fujisawa Pharmaceutical Co New cephem compounds & process for preparation thereof
GB8817653D0 (en) 1988-07-25 1988-09-01 Fujisawa Pharmaceutical Co New cephem compounds & processes for preparation thereof
US5143910A (en) 1989-09-07 1992-09-01 Shionogi & Co., Ltd. Piperaziniocephalosporins
GB9005246D0 (en) 1990-03-08 1990-05-02 Fujisawa Pharmaceutical Co New cephem compounds and processes for preparation thereof
US5095012A (en) * 1990-08-23 1992-03-10 Bristol-Myers Squibb Company Antibiotic c-7 catechol-substituted cephalosporin compounds, compositions, and method of use thereof
GB9111406D0 (en) 1991-05-28 1991-07-17 Fujisawa Pharmaceutical Co New cephem compounds and processes for preparation thereof
GB9118672D0 (en) 1991-08-30 1991-10-16 Fujisawa Pharmaceutical Co New cephem compounds and processes for preparation thereof
PT620225E (pt) 1993-04-16 2003-03-31 Basilea Pharmaceutica Ag Derivados de cefalosporina
EP0838465A1 (en) 1996-10-22 1998-04-29 F. Hoffmann-La Roche Ag Pyridinium-substituted (lactamylvinyl)cephalosporin derivatives, their preparation and their use as antibiotics
DK0841339T3 (da) 1996-11-06 2007-07-02 Basilea Pharmaceutica Ag Vinylpyrrolidinon-cephalosporinderivater
JP2003078440A (ja) 2001-08-30 2003-03-14 Kyocera Corp 高周波スイッチ回路
TW200305422A (en) 2002-03-18 2003-11-01 Shionogi & Co Broad spectrum cefem compounds
JP4557859B2 (ja) 2005-09-29 2010-10-06 富士通株式会社 周波数分割多重送受信装置及び送受信方法
JP2009530228A (ja) 2006-03-16 2009-08-27 アステラス製薬株式会社 セフェム化合物および抗菌薬としての利用
AU2009310959B2 (en) * 2008-10-31 2015-05-07 Shionogi & Co., Ltd. Cephalosporin having catechol group
US8883773B2 (en) * 2010-04-05 2014-11-11 Shionogi & Co., Ltd. Cephem compound having pseudo-catechol group
MX2012011521A (es) * 2010-04-05 2013-03-08 Shionogi & Co Compuestos cefem que tienen un grupo catecol.
WO2011136268A1 (ja) 2010-04-28 2011-11-03 塩野義製薬株式会社 新規なセフェム誘導体
EP2621276B1 (en) * 2010-09-30 2017-12-27 Merck Sharp & Dohme Corp. 2-alkoxy pyrimidine pde10 inhibitors
CA2833121A1 (en) * 2011-04-28 2012-11-01 Shionogi & Co., Ltd. Novel cephem compound having catechol or pseudo-catechol structure
WO2013002215A1 (ja) * 2011-06-27 2013-01-03 塩野義製薬株式会社 ピリジニウム基を有するセフェム化合物
TWI547496B (zh) 2011-10-04 2016-09-01 葛蘭素集團公司 抗菌化合物
WO2013051597A1 (ja) * 2011-10-04 2013-04-11 塩野義製薬株式会社 カテコール基を有するセフェム誘導体
US9527866B2 (en) 2012-10-29 2016-12-27 Shionogi & Co., Ltd. Processes for production of intermediates for 2-alkyl cephem compounds

Also Published As

Publication number Publication date
ZA201502174B (en) 2016-01-27
ES2717923T3 (es) 2019-06-26
CA2889746A1 (en) 2014-05-08
US10174053B2 (en) 2019-01-08
UA117666C2 (uk) 2018-09-10
TWI625333B (zh) 2018-06-01
US20170281532A1 (en) 2017-10-05
CY1121721T1 (el) 2020-07-31
EP2917223A1 (en) 2015-09-16
MX365534B (es) 2019-06-06
SG11201502540RA (en) 2015-05-28
DK2917223T3 (en) 2019-04-15
CR20150224A (es) 2015-10-19
SG10201703589TA (en) 2017-06-29
HK1214826A1 (zh) 2016-08-05
ME03359B (me) 2019-10-20
BR122016025225A2 (pt) 2019-07-30
AR093261A1 (es) 2015-05-27
AU2017200717A1 (en) 2017-02-23
SI2917223T1 (sl) 2019-05-31
PH12017500755A1 (en) 2018-01-29
CL2015001084A1 (es) 2015-08-28
EP2917223B1 (en) 2019-01-16
PH12015500914B1 (en) 2015-06-29
BR112015009460A2 (pt) 2017-07-04
EA201590844A1 (ru) 2015-09-30
MA38039A1 (fr) 2016-05-31
PT2917223T (pt) 2019-05-17
PL2917223T3 (pl) 2019-06-28
HUE042664T2 (hu) 2019-07-29
AU2013340469B2 (en) 2016-11-03
TR201904001T4 (tr) 2019-04-22
PE20151204A1 (es) 2015-09-03
IL238149A (en) 2017-09-28
WO2014068388A1 (en) 2014-05-08
HRP20190603T1 (hr) 2019-05-31
US20150299223A1 (en) 2015-10-22
MY176987A (en) 2020-08-31
JP2015534995A (ja) 2015-12-07
LT2917223T (lt) 2019-04-10
EA031881B1 (ru) 2019-03-29
MX2015005429A (es) 2015-07-21
CN104884460B (zh) 2017-11-03
PH12015500914A1 (en) 2015-06-29
RS58611B1 (sr) 2019-05-31
NZ628527A (en) 2017-03-31
JP6316830B2 (ja) 2018-04-25
KR20150081428A (ko) 2015-07-14
AU2013340469A1 (en) 2015-04-16
TW201431863A (zh) 2014-08-16
CN104884460A (zh) 2015-09-02
CN107652310A (zh) 2018-02-02

Similar Documents

Publication Publication Date Title
UY35103A (es) Compuestos de cefem 2-sustituidos
IN2015DN01198A (es)
PH12019500176A1 (en) Heterocyclic compounds and ther uses
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
TR201813877T4 (tr) Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
MX2014011825A (es) INHIBIDORES DE ISOXAZOL ß-LACTAMASA.
BR112012027439A8 (pt) Derivados de n1-sulfonil-5-flúor-pirimidinona n3-substituídos
MX2016003482A (es) Composiciones antimicrobianas.
NZ702930A (en) Racecadotril liquid compositions
MX2015012416A (es) Compuestos heterociclicos y sus usos.
BR112014030720A8 (pt) composto, composição farmacêutica e usos de inibidores de fbx03
MX2013013649A (es) Compuestos de quinona para tratar enfermedades mediadas por ape1.
MX2016001138A (es) Compuestos de benzoxaborol triciclico, metodo de preparacion y uso del mismo.
EP2995200A4 (en) Sterilization composition with synergism
MX362155B (es) Combinaciones de alquilamidotiazoles y sustancias aromaticas.
MX368268B (es) Formulacion de atazanavir y cobicistat para el tratamiento del virus de inmunodeficiencia humana (vih).
GEP20217236B (en) Composition comprising pentose and polyphenolic compound
MX345263B (es) Formulación de pexiganan estable.
CO7170170A2 (es) Derivados de oxazolidinona 3,4-disustituidos y su uso como inhibidores del canal de potasio activado por calcio
IN2015DN02647A (es)
MX360531B (es) Formulación de aroma y fragancia (ii).
IN2015DN02646A (es)